Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD). - 2025
Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD).
Lok, Christianne; van Trommel, Nienke; Braicu, Elena Ioanaet al.
2025 • In Journal of Clinical Oncology, 43 (18), p. 2119 - 2128
Humans; Female; Pregnancy; Europe; Consensus; Gestational Trophoblastic Disease/therapy; Gestational Trophoblastic Disease/diagnosis; Gestational Trophoblastic Disease; Oncology; Cancer Research
Abstract :
[en] Gestational trophoblastic diseases (GTDs) are a group of pregnancy-related premalignant and malignant diseases with generally a favorable prognosis when treated adequately. Many different treatment protocols exist worldwide. To our knowledge, this is the first set of global consensus-based guidelines for GTD. Four international organizations (European Organisation for the Treatment of Trophoblastic Diseases, European Society of Gynecologic Oncology, Gynecologic Cancer Intergroup, and International Society for the Study of Trophoblastic Diseases) delegated 53 expert GTD clinicians from 31 countries who formulated nine consensus-based definitions and the minimum criteria required to be a GTD center. Furthermore, 18 flow diagrams were developed to diagnose, treat, and follow up all forms of primary or recurrent GTD. The definitions and flow diagrams were drafted and adapted in consecutive (online) meetings until consensus was reached followed by an external review process. Here, the final guidelines are presented together with the available supporting evidence from the literature.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics) Oncology Human health sciences: Multidisciplinary, general & others
Author, co-author :
Lok, Christianne ; Department of Gynaecologic Oncology, Centre of Gynaecologic Oncology Amsterdam, Amsterdam, the Netherlands
van Trommel, Nienke ; Department of Gynaecologic Oncology, Centre of Gynaecologic Oncology Amsterdam, Amsterdam, the Netherlands
Braicu, Elena Ioana ; Department of Gynecology, Center of Oncological Surgery, Charité-University Hospital Berlin, Berlin, Germany
Planchamp, Francois; Institut Bergonié, Bordeaux, France
Berkowitz, Ross; New England Trophoblastic Disease Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Seckl, Michael ; Department of Surgery & Cancer, Charing Cross Hospital Gestational Trophoblastic Disease Center, Charing Cross Hospital Campus of Imperial College London, London, United Kingdom
Goffin, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie-obstétrique, partim Gynécologie ; As a memeber of the EOTTD-ESGO-GCIG-ISSTD Guideline Committee
Language :
English
Title :
Practical Guidelines for the Treatment of Gestational Trophoblastic Disease: Collaboration of the European Organisation for the Treatment of Trophoblastic Disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the Study of Trophoblastic Diseases (ISSTD).
Supported by the European Society of Gynaecological Oncology, which provided an epidemiologist and a project manager who were involved in the development of the guidelines.
Braga A, Lopes R, Campos V, et al: The impact of the distance traveled between residence and gestational trophoblastic neoplasia reference center and clinical outcomes in Brazilian women. Gynecol Oncol 176:130-138, 2023
Joneborg U, Bergamini A, Wallin E, et al: European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors. Int J Gynecol Cancer 33:1621-1626, 2023
World Development Indicators: The World Development Bank, 2023. https://wdi.worldbank.org/tables
Fertility GBD, Forecasting C: Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: A comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet 403:2057-2099, 2024
Lok C, van Trommel N, Massuger L, et al; Clinical Working Party of the E: Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer 130: 228-240, 2020
Ngan HY, Bender H, Benedet JL, et al: Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 83:175-177, 2003 (suppl 1)
Lok C, Frijstein M, van Trommel N: Clinical presentation and diagnosis of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 74:42-52, 2021
Verri D, Pasciuto T, Epstein E, et al: GestaTIonal TrophoblAstic NeoplasIa ultrasound assessMent: TITANIUM study. Int J Gynecol Cancer 29:1216-1220, 2019
Coopmans L, Larsson A, Joneborg U, et al: Surgical management of gestational trophoblastic disease. Gynecol Obstet Invest 89:214-229, 2024
Eysbouts YK, Massuger L, IntHout J, et al: The added value of hysterectomy in the management of gestational trophoblastic neoplasia. Gynecol Oncol 145:536-542, 2017
Kaur B: Pathology of gestational trophoblastic disease (GTD). Best Pract Res Clin Obstet Gynaecol 74:3-28, 2021
McMahon LM, Joyce CM, Cuthill L, et al; hCG working party of the EOTTD: Measurement of hCG in women with gestational trophoblastic disease. Gynecol Obstet Invest 89:178-197, 2024
Tan A, Van der Merwe AM, Low X, et al: Familial HCG syndrome: A diagnostic challenge. Gynecol Oncol Rep 10:47-48, 2014
Sebire NJ, Foskett M, Paradinas FJ, et al: Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet 359:2165-2166, 2002
European Organisation for Treatment of Trophoblastic Diseases. www.eottd.org
International Society for the Study for Trophoblastic Diseases. www.isstd.org
Price JM, Lo C, Abdi S, et al: The role of Computed tomography scanning of the thorax in the initial assessment of gestational trophoblastic neoplasia. Int J Gynecol Cancer 25:1731-1736, 2015
McGrath S, Short D, Harvey R, et al: The management and outcome of women with post-hydatidiform mole’low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l(-1). Br J Cancer 102:810-814, 2010
FIGO Oncology Committee: FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet 77:285-287, 2002
Lawrie TA, Alazzam M, Tidy J, et al: First-line chemotherapy in low-risk gestational trophoblastic neoplasia. Cochrane database Syst Rev 2016:CD007102, 2016
Osborne RJ, Filiaci V, Schink JC, et al: Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A gynecologic oncology group study. J Clin Oncol 29:825-831, 2011
Petrilli ES, Twiggs LB, Blessing JA, et al: Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group. Cancer 60:2173-2176, 1987
Schink JC, Filiaci V, Huang HQ, et al: An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275. Gynecol Oncol 158:354-360, 2020
Osborne RJ, Filiaci VL, Schink JC, et al: Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol 128:535-542, 2016
Alazzam M, Hancock BW, Tidy J: Role of hysterectomy in managing persistent gestational trophoblastic disease. J Reprod Med 53:519-524, 2008
Cortes-Charry R, Hennah L, Froeling FEM, et al: Increasing the human chorionic gonadotrophin cut-off to
Covens A, Filiaci VL, Burger RA, et al: Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Cancer 107:1280-1286, 2006
Winter MC, Tidy JA, Singh K, et al: Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN). Gynecol Oncol 175:66-71, 2023
Mora PAR, Sun SY, Velarde GC, et al: Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia? Gynecol Oncol 153:277-285, 2019
You B, Bolze PA, Lotz JP, et al: Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: Cohort A of the TROPHIMMUN phase II trial. J Clin Oncol 38:3129-3137, 2020
Braga A, Paiva G, Ghorani E, et al: Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: A multicentre, retrospective, cohort study. Lancet Oncol 22: 1188-1198, 2021
Lybol C, Sweep FC, Harvey R, et al: Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol 125: 576-579, 2012
Couder F, Massardier J, You B, et al: Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone. Am J Obstet Gynecol 215:80 e1-e80 e7, 2016
Alifrangis C, Agarwal R, Short D, et al: EMA/CO for high-risk gestational trophoblastic neoplasia: Good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 31: 280-286, 2013
Savage P, Kelpanides I, Tuthill M, et al: Brain metastases in gestational trophoblast neoplasia: An update on incidence, management and outcome. Gynecol Oncol 137:73-76, 2015
Savage P, Winter M, Parker V, et al: Demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma: A UK population study. BJOG 127:1102-1107, 2020
Ji M, Jiang S, Zhao J, et al: Efficacies of FAEV and EMA/CO regimens as primary treatment for gestational trophoblastic neoplasia. Br J Cancer 127:524-530, 2022
Xiao C, Yang J, Zhao J, et al: Management and prognosis of patients with brain metastasis from gestational trophoblastic neoplasia: A 24-year experience in Peking union medical college hospital. BMC Cancer 15:318, 2015
Kaur B, Short D, Fisher RA, et al: Atypical placental site nodule (APSN) and association with malignant gestational trophoblastic disease; a clinicopathologic study of 21 cases. Int J Gynecol Pathol 34:152-158, 2015
Hui P, Webster F, Baergen RN, et al: Dataset for the reporting of gestational trophoblastic neoplasia: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Int J Gynecol Pathol 41:S34-S43, 2022 (suppl 1)
Jeremie G, Allias F, Trecourt A, et al: Molecular analyses of chorionic-type intermediate trophoblastic lesions: Atypical placental site nodules are closer to placental site nodules than epithelioid trophoblastic tumors. Mod Pathol 36:100046, 2023
Marquina G, Szewczyk G, Goffin F: The rare of the rarest: Placental site trophoblastic tumor, epithelioid trophoblastic tumor, atypical placental site nodule. Gynecol Obstet Invest 89:239-246, 2024
Frijstein MM, Lok CAR, van Trommel NE, et al: Management and prognostic factors of epithelioid trophoblastic tumors: Results from the international society for the study of trophoblastic diseases database. Gynecol Oncol 152:361-367, 2019
Schmid P, Nagai Y, Agarwal R, et al: Prognostic markers and long-term outcome of placental-site trophoblastic tumours: A retrospective observational study. Lancet 374:48-55, 2009
Froeling FEM, Ramaswami R, Papanastasopoulos P, et al: Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours. Br J Cancer 120:587-594, 2019
Frijstein MM, Lok CAR, Short D, et al: The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia. Eur J Cancer 109: 162-171, 2019
Fisher RA, Maher GJ: Genetics of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 74:29-41, 2021
Joneborg U, Coopmans L, van Trommel N, et al: Fertility and pregnancy outcome in gestational trophoblastic disease. Int J Gynecol Cancer 31:399-411, 2021
Frijstein MM, Lok C, van Trommel NE, et al: Lung metastases in low-risk gestational trophoblastic neoplasia: A retrospective cohort study. BJOG 127:389-395, 2020
Balachandran K, Salawu A, Ghorani E, et al: When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients. Gynecol Oncol 155:8-12, 2019
Lok CA, van der Houwen C, ten Kate-Booij MJ, et al: Pregnancy after EMA/CO for gestational trophoblastic disease: A report from the Netherlands. BJOG 110:560-566, 2003
Eagles N, Sebire NJ, Short D, et al: Risk of recurrent molar pregnancies following complete and partial hydatidiform moles. Hum Reprod 31:1379, 2016
Faiman C, Ryan RJ, Zwirek SJ, et al: Serum FSH and HCG during human pregnancy and puerperium. J Clin Endocrinol Metab 28:1323-1329, 1968
Bouchard-Fortier G, Ghorani E, Short D, et al: Following chemotherapy for gestational trophoblastic neoplasia, do residual lung lesions increase the risk of relapse? Gynecol Oncol 158:698-701, 2020
Blagden SP, Foskett MA, Fisher RA, et al: The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer 86:26-30, 2002
Williams J, Short D, Dayal L, et al: Effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia. J Reprod Med 59:248-254, 2014
Garcia MT, Lin LH, Fushida K, et al: Pregnancy outcomes after chemotherapy for trophoblastic neoplasia. Rev Assoc Med Bras 62:837-842, 2016
Madi JM, Paganella MP, Litvin IE, et al: Perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia: A systematic review of observational studies and meta-analysis. Am J Obstet Gynecol 226:633-645.e8, 2022
Cai X, Zhang M, Huang C, et al: Association between gestational trophoblastic disease (GTD) history and clinical outcomes in in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles. Reprod Biol Endocrinol 20:27, 2022
Garner E, Goldstein DP, Berkowitz RS, et al: Psychosocial and reproductive outcomes of gestational trophoblastic diseases. Best Pract Res Clin Obstet Gynaecol 17:959-968, 2003
Dhillon T, Palmieri C, Sebire NJ, et al: Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med 51:879-887, 2006
Albright BB, Ellett T, Knochenhauer HE, et al: Treatments and outcomes in high-risk gestational trophoblastic neoplasia: A systematic review and meta-analysis. BJOG 130:443-453, 2023
Jareemit N, Horowitz NS, Goldstein DP, et al: Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. Gynecol Oncol 159: 751-757, 2020
Hanna RK, Soper JT: The role of surgery and radiation therapy in the management of gestational trophoblastic disease. Oncologist 15:593-600, 2010
Baas IO, Westermann AM, You B, et al: Immunotherapy for GTN: A new paradigm. Gynecol Obstet Invest 89:230-238, 2024
